TCR2 Therapeutics selects Cell and Gene Therapy Catapult in the U.K.

TCR2 Therapeutics announced it has selected the advanced therapy medicinal products, or ATMP, ecosystem in the U.K. to establish a site for global manufacturing systems and capabilities. TCR2 will work with Cell and Gene Therapy Catapult at their Stevenage manufacturing center to produce its novel TCR therapies based on the company’s proprietary TRuC T cells. The CGT Catapult manufacturing center was established to allow companies developing cell and gene therapies to manufacture at scale, to Good Manufacturing Practice standards
https://thefly.com/landingPageNews.php?id=2884141